September 19th 2024
"A global consensus on standardization of terminology, separation of LUTS vs pain for outcome, HL positivity and negativity, markers for disease, and the role of new interventions for local vs systemic therapy is needed," writes Gopal H. Badlani, MD.
September 9th 2024
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment
View More
iTind device improves urinary function while preserving sexual function
January 18th 2021Minimally-invasive treatment with the iTind device (Medi-Tate) provides rapid and sustained improvement of LUTS in men with BPH, without adversely affecting patients’ sexual function, according to a recently published 12-month study.
5-year data sustain water vapor thermal therapy benefit in BPH-related LUTS
July 30th 2020Minimally invasive water vapor thermal therapy offers rapid improvements in LUTS, QoL, and flow rate that remain durable to 5 years in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Sulopenem hits key end point in phase 3 uncomplicated UTI trial
June 29th 2020The novel oral penem anti-infective compound sulopenem showed stronger clinical activity than ciprofloxacin in patients with uncomplicated urinary tract infections with quinolone resistant pathogens, according to findings from the phase 3 SURE1 trial.